This promotional material is intended for UK Healthcare Professionals (HCPs) experienced in the diagnosis and management of Parkinson’s disease only. Adverse event reporting can be found below
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
PRODUODOPA is indicated for the treatment of advanced levodopa-responsive Parkinson’s disease (PD) with severe motor fluctuations and hyperkinesia or dyskinesia when available combination of Parkinson’s medicinal products have not given satisfactory results.1
Because levodopa may activate malignant melanoma, PRODUODOPA should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.
Some patients may not be suitable for PRODUODOPA. You are strongly advised to read the Prescribing Information (PI), and Summary of Product Characteristics (SmPC) which can be found via the links above, to evaluate patient suitability for PRODUODOPA.
These promotional events are intended for UK healthcare professionals experienced in the diagnosis and management of advanced Parkinson's disease only.
They have been organised and funded by AbbVie, including payment of speaker honoraria, and will contain information about Produodopa®.
Welcome to the exPloreD events page where you can register for the events of your choice.
Please click on the event you would like to register for and you will be taken to the specific registration page. You can register for more than one event.
Promotional Webinars 2025
AbbVie invites you to register for these promotional webinars, where a panel of experts will explore the management of movement disorders and the use of Produodopa® in clinical practice.
Exploring the Patient Experience
Date: Thursday 13 March 2025
Time: 17:30–18:30
Protocols in Practice
Date: Tuesday 17 June 2025
Time: 17:30–18:30
Promotional Training Meetings 2025
AbbVie invites you to register for these promotional training meetings, where you will be guided through initiating Produodopa® using Vyafuser pump for appropriate patients.
Date: Tuesday 18 March 2025
Time: 10:00–16:00 (Registration: 09:30)
Location: Edinburgh
Date: Wednesday 2 July 2025
Time: 10:00–16:00 (Registration: 09:30)
Location: Birmingham
Date: Thursday 23 October 2025
Time: 10:00–16:00 (Registration: 09:30)
Location: London
In-Person 2-Day Promotional Masterclass
AbbVie invites you to register for this interactive, practical masterclass, where you will have the opportunity to learn more about the implementation of Produodopa® in clinical practice. The sessions will cover topics such as onboarding, managing patient expectations, pump management and practical training.
Date: Thursday 25 to Friday 26 September 2025
Time: Day 1: 10:00–17:30 (Registration: 09:30). Day 2: 09:30–15:00
Location: Birmingham
Please refer to the PRODUODOPA SmPC for further information on adverse events, contraindications and special warnings and precautions for use.
References
- PRODUODOPA (foslevodopa/foscarbidopa solution for infusion) Summary of Product Characteristics.
By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
UK-PRODD-240348. Date of preparation: January 2025.
